Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
40,700
0.00 (0.00%)
At close: Feb 27, 2026
-35.91%
Market Cap 1.19T
Revenue (ttm) 83.13B
Net Income (ttm) -46.63B
Shares Out 29.28M
EPS (ttm) -1,596.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 190,481
Average Volume 425,592
Open 40,000
Previous Close 40,700
Day's Range 39,650 - 41,300
52-Week Range 34,150 - 64,500
Beta 1.20
RSI 47.60
Earnings Date Feb 11, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Sector Technology
Founded 2013
Employees 307
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2025, Lunit's revenue was 83.13 billion, an increase of 53.43% compared to the previous year's 54.18 billion. Losses were -46.63 billion, -43.43% less than in 2024.

Financial Statements

News

There is no news available yet.